Salts of Dasatinib in crystalline form
    2.
    发明授权
    Salts of Dasatinib in crystalline form 有权
    达沙替尼盐结晶

    公开(公告)号:US09556164B2

    公开(公告)日:2017-01-31

    申请号:US14907148

    申请日:2014-07-22

    Applicant: BASF SE

    CPC classification number: C07D417/12 C07B2200/13 C07D275/06

    Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

    Abstract translation: 本发明主要涉及分子结晶物质,优选结晶形式的达沙替尼盐,其包含式1化合物,优选式1化合物的阳离子和选自戊二酸,烟酸 和糖精,优选其阴离子。 本发明还涉及包含这种物质的药物组合物。 此外,本发明涉及制备所述物质的方法。 本发明还涉及使用所述物质或药物组合物治疗疾病的若干方面。

    Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
    4.
    发明授权
    Multicomponent crystalline system comprising nilotinib and selected co-crystal formers 有权
    包括尼罗替尼和选择的共晶体形成剂的多组分结晶体系

    公开(公告)号:US09567317B2

    公开(公告)日:2017-02-14

    申请号:US14433147

    申请日:2013-10-16

    Applicant: BASF SE

    CPC classification number: C07D401/14

    Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

    Abstract translation: 本发明涉及包含尼罗替尼和羧酸,羧酸酯,羧酸酰胺或磺酸作为共晶体形成剂的结晶材料以及包含所述材料的药物组合物。 本发明还涉及制备所述结晶材料的方法以及使用所述结晶材料治疗其中酪氨酸激酶抑制是有益的疾病状况的方法。

Patent Agency Ranking